The Genitourinary Cancer Channel

Explore the latest updates, including expert interviews and features

The GU Cancer Channel on VJOncology is supported by an educational grant from Pfizer Inc. and Merck KGaA. These supporters have no influence over the production of the content.

Latest videos VJSessions Subtypes Topics Conferences Features Editorial Board

Welcome to the Genitourinary (GU) Cancer Channel!

Explore the latest updates presented at major international congresses in the form of video interviews, podcasts and roundtable discussions featuring members of our expert Editorial Board.

Exciting advances are being made in the field of genitourinary cancer, including checkpoint inhibitor treatments, new non-steroidal anti-androgens, chemoimmunotherapy combinations and predictive biomarkers.

GU Cancer Videos by Subtype

Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular Cancer
Penile Cancer
1:13
Promising future of PSMA for prostate cancer
Eugene Shenderov • 10 Jun 2022
6:57
Phase II trial of enoblituzumab for patients with intermediate/high-risk localised prostate cancer
Eugene Shenderov • 10 Jun 2022
2:15
Analyzing the role of oncolytic viruses in prostate cancer
Geertje Van Der Horst • 28 Jun 2022
4:22
Ongoing studies assessing oncolytic virotherapy in urological malignancies
Geertje Van Der Horst • 28 Jun 2022
View All Videos
4:22
Ongoing studies assessing oncolytic virotherapy in urological malignancies
Geertje Van Der Horst • 28 Jun 2022
2:30
The importance of TURBT in bladder cancer management
Kevin Gallagher • 29 Jun 2022
0:57
Future use of liquid biopsies in bladder cancer diagnosis
Kevin Gallagher • 29 Jun 2022
2:35
RESECT: variation in quality of TURBT and its impact on bladder cancer management
Kevin Gallagher • 29 Jun 2022
View All Videos
1:59
Next steps for belzutifan for Von Hippel-Lindau syndrome
Ramaprasad Srinivasan • 17 Jun 2022
13:17
Belzutifan for Von Hippel-Lindau syndrome
Ramaprasad Srinivasan • 17 Jun 2022
5:20
Treatment strategies for Von Hippel-Lindau syndrome
Ramaprasad Srinivasan • 17 Jun 2022
1:59
What is Von Hippel-Lindau syndrome?
Ramaprasad Srinivasan • 17 Jun 2022
View All Videos
7:05
TRISST: MRI versus FDG-PET-CT for the treatment of testicular cancer
Tahlita Zuiverloon • 15 Jul 2021
3:40
Surgery in metastatic germ cell tumors to reduce disease burden and improve long-term outcomes
Peter Albers • 8 Jul 2021
3:34
Benefits of circulating miRNAs for follow-up of patients with seminoma
Matthew Murray • 1 Jul 2021
1:12
miR-371a-3p microRNA panel alone is sufficient for diagnosis and monitoring
Matthew Murray • 1 Jul 2021
View All Videos
3:18
RCC & penile cancer at ASCO GU: KN-564, NeoAvAx & PERICLES
Jen-Jane Liu • 18 Feb 2022
5:44
Long-term outcomes of DSNB for cN0 penile cancer
Edoardo Pozzi • 10 Jul 2021
2:06
c-MET receptor-targeted fluorescence for image-guided surgery in PSCC
Hielke-Martijn De Vries • 7 Jul 2021
3:14
Factors impacting additional tumour-bearing lymph nodes at completion ILND after positive DSNB
Hielke-Martijn De Vries • 7 Jul 2021
View All Videos

Topics

Trial Updates
Molecular Profiling
Immuno-Oncology
Diagnosis
Imaging
6:57
Phase II trial of enoblituzumab for patients with intermediate/high-risk localised prostate cancer
Eugene Shenderov • 10 Jun 2022
2:30
The importance of TURBT in bladder cancer management
Kevin Gallagher • 29 Jun 2022
2:35
RESECT: variation in quality of TURBT and its impact on bladder cancer management
Kevin Gallagher • 29 Jun 2022
1:07
Future developments in the field of radionuclides
Ken Herrmann • 10 May 2022
View All Videos
0:57
Future use of liquid biopsies in bladder cancer diagnosis
Kevin Gallagher • 29 Jun 2022
0:58
Biomarkers associated with PARPi response in patients with castration-resistant prostate cancer
Joe O'Sullivan • 28 Jun 2022
2:04
Areas of unmet need in metastatic urothelial carcinoma
Robert Jones • 4 Jun 2022
1:30
How far away are we from implementing CTC-based approaches in prostate cancer?
Anis Hamid • 6 Jun 2022
View All Videos
1:13
Promising future of PSMA for prostate cancer
Eugene Shenderov • 10 Jun 2022
6:57
Phase II trial of enoblituzumab for patients with intermediate/high-risk localised prostate cancer
Eugene Shenderov • 10 Jun 2022
2:15
Analyzing the role of oncolytic viruses in prostate cancer
Geertje Van Der Horst • 28 Jun 2022
2:40
Limitations of oncolytic viral therapy
Geertje Van Der Horst • 28 Jun 2022
View All Videos
2:30
The importance of TURBT in bladder cancer management
Kevin Gallagher • 29 Jun 2022
5:09
Benefits of upfront staging with PSMA-PET in high-risk prostate cancer
Tobias Maurer • 4 Jul 2022
0:57
Future use of liquid biopsies in bladder cancer diagnosis
Kevin Gallagher • 29 Jun 2022
1:26
Updates in prostate cancer at EAU 2022
Bertrand Tombal • 4 Jul 2022
View All Videos
5:09
Benefits of upfront staging with PSMA-PET in high-risk prostate cancer
Tobias Maurer • 4 Jul 2022
3:44
Salvage treatment options for PSMA-avid lesions
Tobias Maurer • 4 Jul 2022
1:07
Future developments in the field of radionuclides
Ken Herrmann • 10 May 2022
2:06
Optimal tracer for PET-based imaging in prostate cancer
Ken Herrmann • 10 May 2022
View All Videos

Conferences

ASCO 2022
AACR 2022
GU Cancers 2022
ESMO 2021
EAU 2021
ASCO 2021
1:13
Promising future of PSMA for prostate cancer
Eugene Shenderov • 10 Jun 2022
6:57
Phase II trial of enoblituzumab for patients with intermediate/high-risk localised prostate cancer
Eugene Shenderov • 10 Jun 2022
1:59
Next steps for belzutifan for Von Hippel-Lindau syndrome
Ramaprasad Srinivasan • 17 Jun 2022
13:17
Belzutifan for Von Hippel-Lindau syndrome
Ramaprasad Srinivasan • 17 Jun 2022
View All Videos
0:18
Future research directions for the novel PD-1 and CTLA-4 bispecific checkpoint inhibitor, MEDI5752
Ben Tran • 21 Apr 2022
4:28
Update on PETRA trial investigating a next-generation PARP1 select inhibitor
Timothy Yap • 13 Apr 2022
3:30
Radionuclide conjugates 225Ac-J591 and 177Lu-PSMA-I&T for mCRPC
Scott Tagawa • 11 Apr 2022
1:14
Anti-CAIX immune restoring CAR T-cells reverse immunosuppressive TME
Yufei Wang • 11 Apr 2022
View All Videos
3:42
ctDNA level variation as an early predictor of survival in patients with mCRPC
Vincenza Conteduca • 15 Feb 2022
0:53
Unanswered questions in the management of clear cell RCC
Mehmet Bilen • 19 Feb 2022
1:18
URO-12: Importance of collaboration between institutions in clinical trials
Massimo Di Maio • 3 Mar 2022
2:20
Future of PARP inhibitors for urothelial carcinoma
Massimo Di Maio • 3 Mar 2022
View All Videos
3:45
Impacts of COVID-19 infection on patients with urological cancers undergoing surgery
Chuanyu Gao • 7 Jul 2021
3:04
Benefits of T1 substaging for NMIBC
Christiaan De Jong • 21 Jul 2021
4:19
Novel biomarkers for outcomes identified in BCG-treated T1HG bladder cancer
Christiaan De Jong • 21 Jul 2021
3:27
Improving anti-PD-1/PD-L1 therapy for localized bladder cancer
Christiaan De Jong • 21 Jul 2021
View All Videos
4:42
PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients with prostate cancer
Frédéric Pouliot • 4 Jun 2021
4:45
PrE0807: neoadjuvant nivolumab/lirilumab in cisplatin ineligible patients with MIBC
Petros Grivas • 11 Jun 2021
5:49
JAVELIN Bladder 100 trial updates from ASCO 2021
Petros Grivas • 11 Jun 2021
10:12
Trial updates in prostate cancer from ASCO 2021: VISION, PEACE1, & SWOG S1216
Pedro Barata • 8 Jun 2021
View All Videos

The GU Cancer Channel on VJOncology is supported by an educational grant from Pfizer Inc. and Merck KGaA.

These supporters have no influence over the production of the content.

VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals